毕得医药：三名股东计划减持不超3.00%股份

Core Viewpoint - The announcement from Bid Pharma indicates that shareholders Xinxin Management, Landan Management, and Wu Bo plan to reduce their holdings by up to 3.00% within three months after the disclosure date, primarily due to funding needs [1] Shareholder Reduction Plans - Xinxin Management intends to reduce its holdings through block trading by up to 1.14% and through centralized bidding by up to 0.40% [1] - Landan Management plans to reduce its holdings through block trading by up to 0.86% and through centralized bidding by up to 0.40% [1] - Wu Bo aims to reduce his holdings through centralized bidding by up to 0.20% [1] Impact on Company - The reduction in shareholding is not expected to have a significant impact on the company's governance structure, ownership structure, or ongoing operations [1]